Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults-Reference-Cited by-同舟云学术

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

Published:2023-08 Issue:6 Volume:7 Page:102180
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Research and Practice in Thrombosis and Haemostasis

Author:

Konkle Barbara A.,Oldenburg Johannes,Pasi John,Kulkarni Roshni,Nolan Beatrice,Mahlangu Johnny,Young Guy,Brown Simon A.,Pabinger Ingrid,Shapiro Amy,Négrier Claude,Blanchette Victor,Ragni Margaret V.,Dumont Jennifer,Lethagen Stefan

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. WFH guidelines for the management of hemophilia, 3rd edition;Srivastava;Haemophilia,2020

2. The association of haemophilic arthropathy with health-related quality of life: a post hoc analysis;Fischer;Haemophilia,2016

3. Haemophilia and joint disease: pathophysiology, evaluation, and management;Knobe;J Comorb,2011

4. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the joint outcome continuation study;Warren;Blood Adv,2020

5. Extended half-life coagulation factors: a new era in the management of hemophilia patients;Ar;Turk J Haematol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany;Research and Practice in Thrombosis and Haemostasis;2024-07

2. Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry;Haemophilia;2024-04-05